Our Abpromise guarantee covers the use of ab11906 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
EMSA Use at an assay dependent dilution.


  • Function
    Transcription factor involved in osteoblastic differentiation and skeletal morphogenesis. Essential for the maturation of osteoblasts and both intramembranous and endochondral ossification. CBF binds to the core site, 5'-PYGPYGGT-3', of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, osteocalcin, osteopontin, bone sialoprotein, alpha 1(I) collagen, LCK, IL-3 and GM-CSF promoters (By similarity). Inhibits MYST4-dependent transcriptional activation.
  • Tissue specificity
    Specifically expressed in osteoblasts.
  • Involvement in disease
    Defects in RUNX2 are the cause of cleidocranial dysplasia (CLCD) [MIM:119600]; also known as cleidocranial dysostosis (CCD). CLCD is an autosomal dominant skeletal disorder with high penetrance and variable expressivity. It is due to defective endochondral and intramembranous bone formation. Typical features include hypoplasia/aplasia of clavicles, patent fontanelles, wormian bones (additional cranial plates caused by abnormal ossification of the calvaria), supernumerary teeth, short stature, and other skeletal changes. In some cases defects in RUNX2 are exclusively associated with dental anomalies.
  • Sequence similarities
    Contains 1 Runt domain.
  • Domain
    A proline/serine/threonine rich region at the C-terminus is necessary for transcriptional activation of target genes and contains the phosphorylation sites.
  • Post-translational
    Phosphorylated; probably by MAP kinases (MAPK) (By similarity). Isoform 3 is phosphorylated on Ser-340.
  • Cellular localization
  • Information by UniProt
  • Database links
  • Alternative names
    • Acute myeloid leukemia 3 protein antibody
    • Alpha subunit 1 antibody
    • AML3 antibody
    • CBF alpha 1 antibody
    • CBF-alpha-1 antibody
    • CBFA1 antibody
    • CCD antibody
    • CCD1 antibody
    • Cleidocranial dysplasia 1 antibody
    • Core binding factor antibody
    • Core binding factor runt domain alpha subunit 1 antibody
    • Core binding factor subunit alpha 1 antibody
    • Core-binding factor subunit alpha-1 antibody
    • MGC120022 antibody
    • MGC120023 antibody
    • Oncogene AML 3 antibody
    • Oncogene AML-3 antibody
    • OSF 2 antibody
    • OSF-2 antibody
    • OSF2 antibody
    • Osteoblast specific transcription factor 2 antibody
    • Osteoblast-specific transcription factor 2 antibody
    • OTTHUMP00000016533 antibody
    • PEA2 alpha A antibody
    • PEA2-alpha A antibody
    • PEA2aA antibody
    • PEBP2 alpha A antibody
    • PEBP2-alpha A antibody
    • PEBP2A1 antibody
    • PEBP2A2 antibody
    • PEBP2aA antibody
    • PEBP2aA1 antibody
    • Polyomavirus enhancer binding protein 2 alpha A subunit antibody
    • Polyomavirus enhancer-binding protein 2 alpha A subunit antibody
    • Runt domain antibody
    • Runt related transcription factor 2 antibody
    • Runt-related transcription factor 2 antibody
    • RUNX2 antibody
    • RUNX2_HUMAN antibody
    • SL3 3 enhancer factor 1 alpha A subunit antibody
    • SL3-3 enhancer factor 1 alpha A subunit antibody
    • SL3/AKV core binding factor alpha A subunit antibody
    • SL3/AKV core-binding factor alpha A subunit antibody
    see all

Anti-RUNX2 antibody images

  • Nushift polyclonal antibody against AML3 factor creates a supershift in EMSA (lane 4).

References for Anti-RUNX2 antibody (ab11906)

This product has been referenced in:
  • Abdeen AA  et al. Temporal Modulation of Stem Cell Activity Using Magnetoactive Hydrogels. Adv Healthc Mater 5:2536-2544 (2016). Read more (PubMed: 27276521) »
  • Meyer KB  et al. Allele-Specific Up-Regulation of FGFR2 Increases Susceptibility to Breast Cancer. PLoS Biol 6:e108 (2008). EMSA ; Human . Read more (PubMed: 18462018) »

See all 4 Publications for this product

Product Wall

Thank you for sending along your EMSA data. Here are some ideas for potential controls you may consider to clarify the issue: 1) Do you have a control oligo (scrambled) or other labeled oligo to run in the EMSA to determine if ab11906 will bind ...

Read More
Western blot
Mouse Cell lysate - whole cell (MC3T3 mouse embryo/fetus calvaria fibroblasts)
Loading amount
50 µg
MC3T3 mouse embryo/fetus calvaria fibroblasts
Gel Running Conditions
Reduced Denaturing (PAGE 10%)
Blocking step
Milk as blocking agent for 3 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: RT°C

Mr. Cesar Camacho

Verified customer

Submitted May 09 2008

Abcam has not validated the combination of species/application used in this Abreview.
Western blot
Rat Cell lysate - whole cell (osteoblasts UMR-108)
Loading amount
30 µg
osteoblasts UMR-108
Blocking step
Other as blocking agent for 16 hour(s) and 0 minute(s) · Concentration: zymed

Dr. arlene kray

Verified customer

Submitted Jun 07 2006

We usually used 1 to 5 ug of extract in gelshift assays. Oligos used are: wt: 5' CCCGTAT TAA CCA CA AT AAA ACT CG 3' mut: 5' CCC GTA T TAA TGG CA AT AAA ACT CG 3' These oligos are double stranded but I only put here the forward strand in ea...

Read More

Thank you for your enquiry and I'm sorry to hear that you are experiencing difficulty with this antibody. Below is the protocol from the antibody's originator and they used 2-6 ul of antibody/reaction mixture. There have not been any other complaint...

Read More

Thank you for your recent phone call, as discussed on the phone I would recommend running a positive control of nuclear extract of Saos-2 cells and to use more antibody per IP/ChIP (e.g 40-5ul per 500ug lysate/10ug chromatin ) as this antibody is not p...

Read More


Sign up